Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone.

Kähkönen TE, Suominen MI, Mäki-Jouppila JHE, Halleen JM, Tanaka A, Seiler M, Bernoulli J.

J Immunol Res. 2019 May 9;2019:4260987. doi: 10.1155/2019/4260987. eCollection 2019.

2.

Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model.

Kähkönen TE, Tuomela JM, Grönroos TJ, Halleen JM, Ivaska KK, Härkönen PL.

J Bone Oncol. 2019 Mar 19;16:100232. doi: 10.1016/j.jbo.2019.100232. eCollection 2019 Jun.

3.

Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model.

Juzeniene A, Bernoulli J, Suominen M, Halleen J, Larsen RH.

Anticancer Res. 2018 Apr;38(4):1947-1955.

PMID:
29599310
4.

Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio.

Luukkonen J, Pascual LM, Patlaka C, Lång P, Turunen S, Halleen J, Nousiainen T, Valkealahti M, Tuukkanen J, Andersson G, Lehenkari P.

PLoS One. 2017 Aug 8;12(8):e0182904. doi: 10.1371/journal.pone.0182904. eCollection 2017.

5.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A.

Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

6.

Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.

Tang C, Liu Y, Qin H, Li X, Guo W, Li J, Wang W, Qu L, Hu H, Xu C, Zheng L, Huang Y, Liu B, Gao H, Halleen JM, Liu X.

Clin Chim Acta. 2013 Nov 15;426:102-7. doi: 10.1016/j.cca.2013.09.011. Epub 2013 Sep 19.

PMID:
24055775
7.

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.

Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Käkönen SM, Scholz A.

J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16.

PMID:
23682134
8.

Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.

Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM.

Mol Cancer Res. 2012 May;10(5):597-604. doi: 10.1158/1541-7786.MCR-11-0482. Epub 2012 Apr 20.

9.

Models and screening assays for drug discovery in osteoporosis.

Rissanen JP, Halleen JM.

Expert Opin Drug Discov. 2010 Dec;5(12):1163-74. doi: 10.1517/17460441.2010.532484. Epub 2010 Nov 16.

PMID:
22822719
10.

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.

Strube A, Suominen MI, Rissanen JP, Mumberg D, Klar U, Halleen JM, Käkönen SM.

Osteoporos Int. 2011 Nov;22(11):2887-93. doi: 10.1007/s00198-010-1486-9. Epub 2010 Nov 23.

PMID:
21104229
11.

Specificity and clinical performance of two commercial TRACP 5b immunoassays.

Ylipahkala H, Fagerlund KM, Janckila AJ, Houston B, Laurie D, Halleen JM.

Clin Lab. 2009;55(5-6):223-8.

PMID:
19728556
12.

Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.

Fagerlund KM, Janckila AJ, Ylipahkala H, Tiitinen SL, Nenonen A, Cheng S, Uusi-Rasi K, Yam LT, Väänänen HK, Halleen JM.

Clin Lab. 2008;54(9-10):347-54.

PMID:
19097492
13.

Increased osteoclast activity is associated with aggressiveness of osteosarcoma.

Avnet S, Longhi A, Salerno M, Halleen JM, Perut F, Granchi D, Ferrari S, Bertoni F, Giunti A, Baldini N.

Int J Oncol. 2008 Dec;33(6):1231-8.

PMID:
19020756
14.

Improved methods for testing antiresorptive compounds in human osteoclast cultures.

Rissanen JP, Ylipahkala H, Fagerlund KM, Long C, Väänänen HK, Halleen JM.

J Bone Miner Metab. 2009;27(1):105-9. doi: 10.1007/s00774-008-0002-1. Epub 2008 Nov 19.

PMID:
19018457
15.

Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model.

Rissanen JP, Suominen MI, Peng Z, Morko J, Rasi S, Risteli J, Halleen JM.

Calcif Tissue Int. 2008 Feb;82(2):155-61. doi: 10.1007/s00223-007-9101-6. Epub 2008 Jan 25.

PMID:
18219436
16.

Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.

Rissanen JP, Suominen MI, Peng Z, Halleen JM.

Calcif Tissue Int. 2008 Feb;82(2):108-15. Epub 2007 Dec 15.

PMID:
18084692
17.

Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules.

Muhonen P, Avnet S, Parthasarathy RN, Janckila AJ, Halleen JM, Laitala-Leinonen T, Väänänen HK.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):889-95. Epub 2007 Jun 6.

PMID:
17570345
18.

Effects of bioactive peptide, valyl-prolyl-proline (VPP), and lactobacillus helveticus fermented milk containing VPP on bone loss in ovariectomized rats.

Narva M, Rissanen J, Halleen J, Vapaatalo H, Väänänen K, Korpela R.

Ann Nutr Metab. 2007;51(1):65-74. Epub 2007 Mar 15.

PMID:
17356257
19.

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.

Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK.

Clin Lab. 2006;52(9-10):499-509. Review.

PMID:
17078477
20.

Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.

Korpela J, Tiitinen SL, Hiekkanen H, Halleen JM, Selander KS, Väänänen HK, Suominen P, Helenius H, Salminen E.

Anticancer Res. 2006 Jul-Aug;26(4B):3127-32.

21.

Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase.

Fagerlund KM, Ylipahkala H, Tiitinen SL, Janckila AJ, Hamilton S, Mäentausta O, Väänänen HK, Halleen JM.

Arch Biochem Biophys. 2006 May 15;449(1-2):1-7. Epub 2006 Mar 27.

PMID:
16620768
22.

Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.

Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM.

J Bone Miner Res. 2005 Oct;20(10):1804-12.

23.

Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls.

Wang Q, Alén M, Nicholson PH, Halleen JM, Alatalo SL, Ohlsson C, Suominen H, Cheng S.

J Clin Endocrinol Metab. 2006 Jan;91(1):277-82. Epub 2005 Oct 25.

PMID:
16249282
24.

Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.

Salminen E, Ala-Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK.

Acta Oncol. 2005;44(7):742-7.

PMID:
16227166
25.

Endogenous expression and endocytosis of tartrate-resistant acid phosphatase (TRACP) by osteoblast-like cells.

Perez-Amodio S, Vogels IM, Schoenmaker T, Jansen DC, Alatalo SL, Halleen JM, Beertsen W, Everts V.

Bone. 2005 Jun;36(6):1065-77.

PMID:
15878315
26.

Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing.

Räisänen SR, Alatalo SL, Ylipahkala H, Halleen JM, Cassady AI, Hume DA, Väänänen HK.

Biochem Biophys Res Commun. 2005 May 27;331(1):120-6.

PMID:
15845367
27.

Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells.

Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Hsueh YC, Rissanen J, Alatalo SL, Halleen JM, Yam LT.

J Leukoc Biol. 2005 Feb;77(2):209-18. Epub 2004 Nov 12.

PMID:
15542543
28.

Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.

Vääräniemi J, Halleen JM, Kaarlonen K, Ylipahkala H, Alatalo SL, Andersson G, Kaija H, Vihko P, Väänänen HK.

J Bone Miner Res. 2004 Sep;19(9):1432-40. Epub 2004 Jun 14.

29.

Effects of Lactobacillus helveticus fermented milk on bone cells in vitro.

Narva M, Halleen J, Väänänen K, Korpela R.

Life Sci. 2004 Aug 20;75(14):1727-34.

PMID:
15268972
30.

Biochemical markers of bone metabolism and prediction of fracture in elderly women.

Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ.

J Bone Miner Res. 2004 Mar;19(3):386-93. Epub 2003 Dec 22.

31.

Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).

Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM.

Clin Chem. 2004 May;50(5):883-90. Epub 2004 Mar 11.

32.

Potential function for the ROS-generating activity of TRACP.

Halleen JM, Räisänen SR, Alatalo SL, Väänänen HK.

J Bone Miner Res. 2003 Oct;18(10):1908-11. Review.

33.

Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls.

Cheng S, Tylavsky F, Kröger H, Kärkkäinen M, Lyytikäinen A, Koistinen A, Mahonen A, Alen M, Halleen J, Väänänen K, Lamberg-Allardt C.

Am J Clin Nutr. 2003 Sep;78(3):485-92. Erratum in: Am J Clin Nutr. 2006 Jan;83(1):174.

PMID:
12936933
34.

Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial.

Uusi-Rasi K, Kannus P, Cheng S, Sievänen H, Pasanen M, Heinonen A, Nenonen A, Halleen J, Fuerst T, Genant H, Vuori I.

Bone. 2003 Jul;33(1):132-43.

PMID:
12919708
35.

Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium.

Ylipahkala H, Halleen JM, Kaija H, Vihko P, Väänänen HK.

Biochem Biophys Res Commun. 2003 Aug 22;308(2):320-4.

PMID:
12901871
36.
37.

A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum.

Alatalo SL, Peng Z, Janckila AJ, Kaija H, Vihko P, Vaananen HK, Halleen JM.

J Bone Miner Res. 2003 Jan;18(1):134-9.

38.

Does hysterectomy with ovarian conservation affect bone metabolism and density?

Cheng S, Sievänen H, Heinonen A, Uusi-Rasi K, Carbone L, Tylavsky F, Halleen J, Kannus P.

J Bone Miner Metab. 2003;21(1):12-6.

PMID:
12491088
39.

Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.

Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK.

Calcif Tissue Int. 2002 Jul;71(1):20-5. Epub 2002 Jun 20.

PMID:
12073156
40.

Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.

Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT.

Clin Chim Acta. 2002 Jun;320(1-2):49-58.

PMID:
11983200
41.

Two different pathways for the maintenance of trabecular bone in adult male mice.

Lindberg MK, Movérare S, Skrtic S, Alatalo S, Halleen J, Mohan S, Gustafsson JA, Ohlsson C.

J Bone Miner Res. 2002 Apr;17(4):555-62.

42.

Alendronate disturbs vesicular trafficking in osteoclasts.

Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K.

Calcif Tissue Int. 2002 Jan;70(1):40-7. Epub 2001 Dec 21.

PMID:
11907706
43.

Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent.

Kaija H, Alatalo SL, Halleen JM, Lindqvist Y, Schneider G, Väänänen HK, Vihko P.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):128-32.

PMID:
11890682
44.

Does combined gastrectomy and ovariectomy induce greater osteopenia in young female rats than gastrectomy alone?

Surve VV, Andersson N, Alatalo S, Lehto-Axtelius D, Halleen J, Väänänen K, Håkanson R.

Calcif Tissue Int. 2001 Nov;69(5):274-80.

PMID:
11768197
45.

Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice.

Lindberg MK, Erlandsson M, Alatalo SL, Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson JA, Ohlsson C.

J Endocrinol. 2001 Dec;171(3):425-33.

PMID:
11739008
46.

Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts.

Parikka V, Lehenkari P, Sassi ML, Halleen J, Risteli J, Härkönen P, Väänänen HK.

Endocrinology. 2001 Dec;142(12):5371-8.

PMID:
11713237
47.

Estrogen receptor specificity in the regulation of the skeleton in female mice.

Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C.

J Endocrinol. 2001 Nov;171(2):229-36.

PMID:
11691642
48.

Tartrate-resistant acid phosphatase facilitates hydroxyl radical formation and colocalizes with phagocytosed Staphylococcus aureus in alveolar macrophages.

Räisänen SR, Halleen J, Parikka V, Väänänen HK.

Biochem Biophys Res Commun. 2001 Oct 19;288(1):142-50.

PMID:
11594765
49.

Tartrate-resistant acid phosphatase as a serum marker of bone resorption.

Halleen JM, Ranta R.

Am Clin Lab. 2001 Jul;20(6):29-30. Review. No abstract available.

PMID:
11480390
50.

Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption.

Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK.

Clin Chem. 2001 Mar;47(3):597-600. No abstract available.

Supplemental Content

Loading ...
Support Center